美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-060 美康生物科技股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 10 月 28 日在公司会议室以现场结合通讯方式召开，会议通知已于 2025 年 10 月 18 日以电话、邮件等方式送达全体董事。会议应出席董事 5 人， 实际出席董事 5 人，会议由董事长邹炳德先生召集并主持。本次会议的召集、召 开符合《中华人民共和国公司法》（以下简称"《公司法》"）《美康生物科技 股份有限公司章程》（以下简称"《公司章程》"）等有关规定，合法有效。 经与会董事审议与表决，本次会议决议如下： 一、审议并通过《关于公司<2025 年第三季度报告>的议案》 公司编制了《美康生物科技股份有限公司 2025 年第三季度报告》。报告内 容真实、准确、完整地反映了公司 2025 年第三季度经营的实际情况，不存在任 何虚假记载、误导性陈述或者重大遗漏。 表决结果： ...

Financial Performance - Q3 2025 revenue was CNY 399,447,767.69, a decrease of 12.71% year-over-year[5] - Net profit attributable to shareholders was CNY 3,700,056.84, down 91.94% compared to the same period last year[5] - Net profit excluding non-recurring items was CNY 1,182,138.59, a decline of 97.25% year-over-year[5] - Total operating revenue decreased to ¥1,135,669,290.81 from ¥1,406,709,821.37, a decline of approximately 19.3%[23] - Operating profit fell to ¥54,101,653.44 from ¥250,212,726.27, representing a decrease of approximately 78.4%[24] - Net profit decreased to ¥58,893,569.05 from ¥223,329,538.72, a decline of around 73.7%[24] - Earnings per share dropped to ¥0.1576 from ¥0.5844, a decrease of approximately 73.0%[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,655,246,461.86, a decrease of 1.35% from the previous year[5] - The total non-current assets decreased from ¥1,880,920,162.34 to ¥1,775,350,820.43, representing a decline of about 5.6%[20] - The company’s total current liabilities decreased from ¥667,437,831.62 to ¥602,922,198.57, a decline of approximately 9.7%[20] - Total liabilities decreased to ¥706,758,428.14 from ¥771,646,162.98, a decline of approximately 8.4%[21] - The company’s total equity attributable to shareholders was CNY 2,955,784,542.29, an increase of 0.54% from the previous year[5] - Total equity increased to ¥2,948,488,033.72 from ¥2,933,468,343.82, an increase of about 0.5%[21] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 144,977,744.95, an increase of 32.96%[10] - Cash flow from operating activities for the current period is 144,977,744.95, an increase from 109,039,623.15 in the previous period[25] - Total cash inflow from investment activities is 723,164,208.45, up from 479,909,809.39 in the previous period[25] - Net cash flow from investment activities is -150,217,872.40, an improvement from -393,618,233.08 in the previous period[25] - Cash flow from financing activities shows a net outflow of -90,497,945.04, compared to -78,095,542.21 in the previous period[26] - The ending balance of cash and cash equivalents is 630,389,667.97, compared to 590,804,894.43 in the previous period[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 23,895[11] - The number of shares held by the top shareholder, Zou Bingde, is 108,897,635, representing a 28.34% ownership stake[14] - The company has a total of 91,986,764 restricted shares at the end of the period, down from 92,036,764 at the beginning, indicating a slight reduction in restricted shares[17] Other Financial Metrics - The weighted average return on equity was 0.13%, down 1.50% from the previous year[5] - The company reported a significant decrease in financial expenses by 71.08% due to interest income from structured deposits[9] - Deferred income increased to ¥27,170,000.04 from ¥17,020,000.02, an increase of about 59.8%[21] - Research and development expenses decreased to ¥103,113,005.51 from ¥114,751,323.89, a decline of approximately 10.2%[24] - Other comprehensive income after tax increased to ¥1,261,533.54 from -¥4,248,904.58, a significant improvement[24]

Policy Developments - The National Medical Products Administration (NMPA) is enhancing support for medical device research and innovation, aiming to improve the efficiency of review and approval processes, and accelerate the market entry of innovative products [2] Company Announcements - SanegeneBio's SGB-9768, a targeted C3 siRNA drug, has received Orphan Drug Designation from the FDA for treating C3 glomerulopathy, with a promising subcutaneous administration regimen [4] - Meikang Bio has obtained three medical device registration certificates for in vitro diagnostic reagents, which will enhance its product line and market competitiveness [5] - Meihua Medical reported a 19.25% decline in net profit for the first three quarters of 2025, despite a 3.28% increase in revenue [7] - China National Pharmaceutical Group (Sinopharm) reported a 13.10% increase in net profit for the third quarter of 2025, with a revenue growth of 3.58% [8] - Aiwai Technology announced a 10 million yuan investment in Luying Technology, acquiring a 9.07% stake, although Luying is still in the development phase with no sales revenue [10] - Yingke Medical's subsidiary plans to invest 70 million USD in a fund with a target size of 17 billion USD [12] Industry Developments - A breakthrough in oral insulin delivery has been achieved by a team from Beihang University, significantly improving the bioavailability of oral insulin to 20.4%, which is over 20 times that of traditional formulations [14] - Science Corporation has developed a retinal microchip implant that restores vision to blind patients, allowing them to read and engage in activities like crossword puzzles [15] - In the first eight months of this year, Beijing's medical instrument and device exports reached 5.83 billion yuan, a 21.5% increase year-on-year [16]

（文章来源：证券日报） 证券日报网讯 10月21日晚间，美康生物发布公告称，公司近日取得了浙江省药品监督管理局颁发的 《中华人民共和国医疗器械注册证（体外诊断试剂）》。 ...

格隆汇10月21日丨美康生物(300439.SZ)公布，近日取得了由浙江省药品监督管理局颁发的《中华人民 共和国医疗器械注册证（体外诊断试剂）》。上述《注册证》的取得，丰富了公司在体外诊断生化及化 学发光细分领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能力，对公司未来的经 营将产生积极影响。 | 序号 | 注册人名称 | 产品名称 | 注册证编号 | 注册证有效期间 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 美康生物 | 25-羟基维生素 D 检 测试剂盒(胶乳免疫 | 浙 械 注 准 | 2025 年9月 26日至 | 用于体外定量测定人血清 中 25-羟基维生素 D 的浓 | | | | 比浊法) | 20252401757 | 2030年9月25日 | 度。 | | 2 | 美康生物 | 胆酸检测试剂盒(胶 乳免疫比浊法) | 浙 械 注 准 20252401793 | 2025年10月12日至 2030 年 10月 11日 | 用于体外定量测定人血清 中胆酸的浓度。 | | ਤੇ | 美康生物 | 胰岛素样生长因子-I 检 ...

Group 1 - Meikang Biotech has recently obtained the Medical Device Registration Certificate issued by the Zhejiang Provincial Drug Administration [1] - The registered products include the "25-Hydroxyvitamin D Test Kit" among others [1] Group 2 - The interview with He Keng emphasizes the need to shift funding focus from excessive investment in housing and infrastructure to enhancing social welfare [1]

证券代码：300439 证券简称：美康生物 公告编号：2025-057 美康生物科技股份有限公司 美康生物科技股份有限公司 关于公司取得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美康生物科技股份有限公司(以下简称"美康生物"或"公司")于近日取得 了由浙江省药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断 试剂）》（以下简称"《注册证》"），具体情况如下： | 序号 | 注册人名称 | 产品名称 | | 注册证编号 | | 注册证有效期间 | | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 美康生物 | 25-羟基维生素 D 测试剂盒(胶乳免疫 | 检 | 浙 械 注 准 | 年 2025 | 9 | 月 26 | 日至 | 用于体外定量测定人血清 中 25-羟基维生素 D 的浓 | | | | 比浊法） | | 20252401757 | 2030 年 | 9 月 | 25 | 日 | 度。 | | 2 | 美 ...

美康生物科技股份有限公司 证券代码：300439 证券简称：美康生物 公告编号：2025-058 近日，公司在上述使用期限及额度内使用部分闲置募集资金进行现金管理， 具体情况如下： 一、本次使用部分闲置募集资金进行现金管理的进展情况 单位：人民币万元 | 序 号 | 受托人名称 | 产品名称 | 产品类型 | | 委托理 财金额 | 起始日 | 到期日 | 预计年化收益 率 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 中国银行宁波 下应支行 | 挂钩型结构 性存款 | 保 本 浮 收 益 型 | 动 理 | 2,450.00 | 2025/10/20 | 2026/1/28 | 0.59%-2.70% | | | | | 财产品 | | | | | | | 2 | 中国银行宁波 下应支行 | 挂钩型结构 性存款 | 保 本 浮 收 益 型 | 动 理 | 2,550.00 | 2025/10/21 | 2026/1/30 | 0.6%-2.62% | | | | | 财产品 | | | | | | 注：公司与上述产品受托人不存 ...

Core Viewpoint - The company anticipates pressure on domestic revenue and profits in 2025 due to the full implementation of policies such as centralized procurement, disassembly of testing packages, and standardization of charging [2] Group 1: Domestic Market Strategy - The company's self-produced revenue is primarily composed of biochemical products, with most biochemical projects included in the centralized procurement scope after three rounds of inter-provincial alliance procurement for liver function, kidney function, and glucose metabolism [2] - The company plans to enhance refined management, implement large-scale production, optimize the supply chain, and increase operational efficiency to improve market share and brand influence in the immunological products sector [2] Group 2: Growth Initiatives - The company will accelerate its overseas market expansion and aims to create new performance growth points domestically through precision diagnostic products such as mass spectrometry and precise blood lipid testing [2]

Core Viewpoint - Meikang Bio primarily engages in the research, production, and sales of in vitro diagnostic products, as well as providing third-party medical diagnostic services. The company has indicated that any future developments in brain-computer interface technology will comply with relevant laws and regulations regarding information disclosure [1] Group 1 - The company focuses on in vitro diagnostic products and related services [1] - Future developments in brain-computer interface technology will adhere to legal and regulatory requirements [1]